Brainstorm cell therapeutics to meet with us fda to discuss development plan for nurown as a treatment of als

-  path forward for als is a registrational phase 3b u.s. clinical trial - -  biologics license application to be withdrawn without prejudice - -  conference call and webcast at 8:30am et today - new york , oct. 18, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the us food and drug administration (fda) has invited the company to request an expedited face-to-face meeting to discuss the path forward for nurown® as a treatment for amyotrophic lateral sclerosis (als). brainstorm remains committed to the als community and is actively exploring the next steps in support of nurown, including publication of emerging clinical data and development of a protocol for an additional clinical study.
BCLI Ratings Summary
BCLI Quant Ranking